Nanovibronix (NASDAQ:FEED – Get Free Report) and TransEnterix (OTCMKTS:TRXDW – Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.
Institutional & Insider Ownership
16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 8.2% of TransEnterix shares are held by institutional investors. 1.4% of Nanovibronix shares are held by company insiders. Comparatively, 3.1% of TransEnterix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Nanovibronix and TransEnterix”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nanovibronix | $2.69 million | 1.17 | -$3.70 million | ($41.74) | -0.07 |
| TransEnterix | $8.53 million | 2.51 | -$154.20 million | ($4.22) | -0.04 |
Nanovibronix has higher earnings, but lower revenue than TransEnterix. Nanovibronix is trading at a lower price-to-earnings ratio than TransEnterix, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Nanovibronix has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, TransEnterix has a beta of 2.56, meaning that its share price is 156% more volatile than the S&P 500.
Profitability
This table compares Nanovibronix and TransEnterix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanovibronix | -275.12% | -24.78% | -19.24% |
| TransEnterix | -2,149.15% | -83.74% | -64.94% |
Analyst Ratings
This is a summary of recent ratings for Nanovibronix and TransEnterix, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
| TransEnterix | 0 | 0 | 0 | 0 | 0.00 |
Summary
Nanovibronix beats TransEnterix on 7 of the 12 factors compared between the two stocks.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
About TransEnterix
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
